← Neuronetics, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | $40.4m |
$52.8m
+30.53%
|
$62.7m
+18.72%
|
$49.2m
-21.41%
|
$55.3m
+12.32%
|
$65.2m
+17.89%
|
$71.3m
+9.42%
|
$74.9m
+4.96%
|
$149.2m
+99.17%
|
$151.6m
+1.66%
|
|
| Total Cost of revenues | $9.6m |
$12.4m
+29.23%
|
$15.4m
+23.64%
|
$11.6m
-24.92%
|
$11.7m
+0.86%
|
$15.5m
+32.87%
|
$19.6m
+26.87%
|
$20.7m
+5.53%
|
$76.8m
+270.73%
|
— | |
| Gross profit | $30.8m |
$40.3m
+30.93%
|
$47.3m
+17.20%
|
$37.7m
-20.26%
|
$43.7m
+15.84%
|
$49.7m
+13.89%
|
$51.7m
+3.99%
|
$54.2m
+4.75%
|
$72.3m
+33.51%
|
$72.7m
+0.58%
|
|
| Research and development | $7.9m | $8.2m | $13.7m | $9.2m | $7.9m | $9.3m | $9.5m | $12.8m | $6.6m | $6.3m | |
| Sales and marketing | $27.9m | $38.3m | $43.0m | $32.6m | $37.7m | $50.0m | $47.3m | $45.6m | $47.5m | — | |
| General and administrative | $8.6m | $13.7m | $17.5m | $18.2m | $25.6m | $25.5m | $25.4m | $30.3m | $49.7m | $49.6m | |
| Total operating expenses | $44.4m | $60.2m | $74.2m | $60.0m | $71.2m | $84.8m | $82.3m | $88.7m | $103.7m | $102.1m | |
| Loss from operations | ($13.6m) |
($19.8m)
-45.75%
|
($26.9m)
-35.78%
|
($22.3m)
+17.16%
|
($27.6m)
-23.56%
|
($35.1m)
-27.38%
|
($30.6m)
+12.98%
|
($34.6m)
-13.12%
|
($31.4m)
+9.05%
|
— | |
| Interest expense | $2.8m | $3.7m | $3.7m | $4.5m | $4.0m | $4.3m | $5.4m | $7.3m | $8.4m | $7.9m | |
| Other income, net | ($357k) | $575k | ($1.6m) | ($302k) | ($390k) | ($2.2m) | ($5.8m) | ($2.5m) | ($716k) | $950k | |
| Net loss | — | — | — | — | — | ($37.2m) | ($30.2m) | ($43.7m) | ($39.1m) | — | |
| Less: Net loss attributable to non-controlling interest | — | — | — | — | — | — | — | $19k | ($137k) | — | |
| Net loss attributable to Neuronetics stockholders' | ($16.1m) | ($24.1m) | ($29.0m) | ($27.5m) | ($31.2m) | ($37.2m) | ($30.2m) | ($43.7m) | ($39.0m) | — | |
| Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders' | ($86) | ($3) | ($2) | ($1) | ($1) | ($1) | ($1) | ($1) | ($1) | — | |
| Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders' | ($86) | ($3) | ($2) | ($1) | ($1) | ($1) | ($1) | ($1) | ($1) | — | |
| Weighted average common shares outstanding, basic (in shares) | — | — | 18.4m | 18.8m | 25.5m | 26.9m | 28.7m | 31.7m | 66.0m | — | |
| Weighted average common shares outstanding, diluted (in shares) | — | — | 18.4m | 18.8m | 25.5m | 26.9m | 28.7m | 31.7m | 66.0m | — | |
| Loss on extinguishment of debt | — | — | — | $924k | — | — | — | $4.4m | — | — |